FDA accepts Pfizer-Sanofi application for insulin inhaler

03/4/2005 | Wall Street Journal, The

Pfizer and Sanofi-Aventis, partners in developing a form of insulin that is inhaled, said the U.S. FDA accepted its application and will review the product, called Exubera, which delivers the insulin in a dry-powder form. The companies plan to co-market the inhaler for adults with Type 1 and Type 2 diabetes, making it the first form of insulin given by means other than an injection or a pump. San Carlos, Calif.-based Nektar Therapeutics developed both the inhaler and the dry form of insulin.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX